| 6.26 -0.04 (-0.63%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.08 | 1-year : | 10.61 |
| Resists | First : | 7.78 | Second : | 9.08 |
| Pivot price | 6.28  |
|||
| Supports | First : | 5.1 |
Second : | 3.44 |
| MAs | MA(5) : | 6.38 |
MA(20) : | 5.74 |
| MA(100) : | 4.21 |
MA(250) : | 4.7 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 61.3 |
D(3) : | 63.5 |
| RSI | RSI(14): 62.9 |
|||
| 52-week | High : | 7.78 | Low : | 3.09 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BOLT ] has closed above bottom band by 49.1%. Bollinger Bands are 76.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.39 - 6.44 | 6.44 - 6.47 |
| Low: | 6.07 - 6.13 | 6.13 - 6.17 |
| Close: | 6.19 - 6.27 | 6.27 - 6.33 |
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
Mon, 09 Nov 2026
Bolt Biotherapeutics, Inc. (BOLT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 06 Nov 2026
Five reporting persons report the same stake in Bolt Biotherapeutics (BOLT). - Stock Titan
Tue, 03 Nov 2026
Bolt Biotherapeutics to Participate in Upcoming Conferences - Yahoo Finance
Thu, 29 Oct 2026
Bolt Biotherapeutics, Inc. (BOLT) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada
Mon, 26 Oct 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) - Morningstar
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 5.4 (%) |
| Held by Institutions | 20.6 (%) |
| Shares Short | 16 (K) |
| Shares Short P.Month | 18 (K) |
| EPS | -16.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.55 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.38 |
| PEG Ratio | 0 |
| Price to Book value | 0.95 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|